Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2015 Sep;24(137):375-7.
doi: 10.1183/16000617.0051-2015.

Rare pulmonary diseases and orphan drugs: where do we stand and where are we going to?

Sergio Harari  1 , Marc Humbert  2 , Francesco Blasi  3 , Harold R Collard  4 , Marco Matucci-Cerinic  5 , Gerald Simonneau  2 , Carlo Vancheri  6 , Athol U Wells  7 , Vincent Cottin  8
Affiliations
Editorial

Rare pulmonary diseases and orphan drugs: where do we stand and where are we going to?

Sergio Harari et al. Eur Respir Rev. 2015 Sep.

Abstract

Updates on rare pulmonary diseases from the 6th International Meeting on Pulmonary Rare Diseases and Orphan Drugs http://ow.ly/PYUCC

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: Disclosures can be found alongside the online version of this article at err.ersjournals.com

References

    1. Harari S, Lau EM, Tamura Y, et al. . Rare (pulmonary) disease day: “feeding the breath, energy for life!” Eur Respir J 2015; 45: 297–300. - PubMed
    1. Spagnolo P, du Bois RM, Cottin V. Rare lung disease and orphan drug development. Lancet Respir Med 2013; 1: 479–487. - PubMed
    1. Cordier JF, Cottin V. Orphan lung diseases from definition to organisation of care. In: Cottin V, Cordier JF, Richeldi L, eds. Orphan Lung Diseases: A Clinical Guide to Rare Lung Disease. London, Springer-Verlag, 2015; pp. 1–3.
    1. Harari S, Humbert M, Cottin V. Future perspectives on rare pulmonary diseases and rare presentations of common disorders. Eur Respir Rev 2013; 22: 199–201. - PMC - PubMed
    1. Raghu G, Collard HR, Anstrom KJ, et al. . Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med 2012; 185: 1044–1048. - PMC - PubMed

Publication types

Substances